Didymin ameliorates dexamethasone-induced non-alcoholic fatty liver disease by inhibiting TLR4/NF-κB and PI3K/Akt pathways in C57BL/6 J mice - Feng, Z; Pang, L; Chen, S; Pang, X; Huang, Y; Qiao, Q (Int Immunopharmacol, 2020)